Results 111 to 120 of about 35,812 (218)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, Volume 20, Issue 10, Page 2424-2448, October 2026.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, Volume 20, Issue 10, Page 2533-2566, October 2026.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, Volume 20, Issue 10, Page 2510-2532, October 2026.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

Single‐Cell Dissection of Therapy‐Induced Remodeling Uncovers a Fibroblast‐Driven Immunosuppressive Niche and Targetable Vulnerabilities in Lethal Prostate Cancer

Advanced Science, Volume 13, Issue 56, 9 October 2026.
Single‐cell longitudinal profiling reveals that androgen‐deprivation therapy induces a DPT+ fibroblast‐complement axis that suppresses macrophage inflammation and drives CD8+ T cell exhaustion in prostate cancer. Concurrently, resistant epithelial subpopulations persist and engage TSPAN1‐ and NRXN1‐mediated programs promoting CRPC and neuroendocrine ...
Yang Chen, Dandan Dong, Jinling Liao, Naikai Liao, Mengqi Liu, Qin Zhang, Siting Chen, Qi Liu, Ying Lu, Tianyu Li, Chunlin Zou, Qiong Song, Qiuyan Wang, Jian Liang, Qiji Xie, Chengyang Li, Mengyun Wang, Jiwen Cheng, Zengnan Mo, Gong‐Hong Wei   +19 more
wiley   +1 more source

In Situ Self‐Assembled Molecular Fortifying Agent for Enhanced Retention and Therapeutic Efficacy of Radiopharmaceuticals

Aggregate, Volume 7, Issue 10, October 2026.
A molecular‐fortifying agent strategy based on in situ self‐assembly is developed to prolong tumor retention of radioligands. After tumor‐targeting, FAP‐α cleavage triggers nanofiber formation, presenting azide anchors for bioorthogonal capture of pre‐accumulated radioligands.
Daojia Liu, Xiaoqin Luo, Xiaojuan Wang, Xing Liu, Fanglei Zhang, Pan Wang, Jibin Song, Junqiang Chen   +7 more
wiley   +1 more source

Metastatic intrigue: Penile involvement in prostate cancer with neuroendocrine differentiation—A case report

UroPrecision
Background Neuroendocrine carcinoma of the prostate is a rare tumor subtype found in the spectrum of prostate cancer, and is more difficult to detect, due to the low prostate‐specific antigen values associated with it. A high degree of suspicion is hence
Uttam Kumar Mete, Neha Bhardwaj, Radhika Srinivasan, Rohit Sanjay Deshpande   +3 more
doaj   +1 more source

Neuroendocrine differentiation in prostate cancer.

American journal of translational research, 2011
As any organ in the body human prostate is composed of many different types of cells as well as extracellular components. During prostate development, reciprocal cellular interactions between stromal cells and prostate epithelial cells ultimately lead to the development of a mature prostate.
Yin, Sun, Junyang, Niu, Jiaoti, Huang
openaire   +1 more source

A Rapid and Sensitive LC–MS/MS Method for Quantification of NDSRI in Melatonin Drug Product via Controlled In Situ Formation

Biomedical Chromatography, Volume 40, Issue 10, October 2026.
ABSTRACT Nitrosamine drug substance–related impurities (NDSRIs) pose a significant safety risk due to their mutagenic and carcinogenic potential, prompting strict regulatory oversight under ICH M7. The propensity for in situ formation of NDSRIs during analytical procedures, particularly in active pharmaceutical ingredients containing reactive amines ...
Jaya Yalamanchili, Ganja Himavathi, Salakolusu Suresh   +2 more
wiley   +1 more source

Next‐Generation Sequencing‐Based Molecular Profiling and Management of Advanced Solid Tumors: A Real‐World Experience in a Community‐Based Academic Cancer Center

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Advances in molecular and cell biology have led to a paradigm shift in cancer management. We implemented next‐generation sequencing (NGS) at our community‐based academic cancer center over a decade ago. We sought to optimize the use of genomics and understand its impact in identifying actionable genomic alterations to determine ...
Gayathri Moorthy, Annette Sereika, Karen Kaul, Megan Parilla, Mir B. Alikhan, Michael Bouma, Dyson Wake, Peter J. Hulick, Henry M. Dunnenberger, Linda M. Sabatini, Mathew Yang, Kathy A. Mangold, Erin Proctor, Nicholas Evans, Nicholas Miller, Donald L. Helseth Jr, Darryck Maurer, Justin Brueck, Janardan Khandekar, Bruce Brockstein   +19 more
wiley   +1 more source

Patient and Caregiver Reported Barriers to Cancer Clinical Trial Participation: A Scoping Review

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background The development of cancer treatments relies on patient participation in clinical trials, yet poor recruitment and retention hinder evidence generation. There exists an urgent need for trial designs that address patient‐identified barriers, informational gaps, and concerns. The goal of this evidence synthesis was to identify patient‐
Sarah Scruton, Chisato Ito, Julia Bohnen, Robin Urquhart, Chiquita Hessels, Summer Konechny, Rosilene Kraft, Randy Thompson, Cheryl Ho, Deirdre Weymann, Yvonne Bombard, Emanuel Krebs, Avram Denburg, Timothy P. Hanna, Howard J. Lim, Saadia Shareen, Dean A. Regier, Samantha Pollard   +17 more
wiley   +1 more source